Remove Bioavailability Remove Clinical Development Remove Containment Remove Gene Silencing
article thumbnail

Vevye: A New Cyclosporine Solution for Dry Eye Disease

XTalks

Furthermore, the bioavailability of the active pharmaceutical ingredient (API) into the cornea is up to four times stronger with EyeSol technology. percent is an immunosuppressant in the class of calcineurin inhibitors, specifically developed for treating the signs and symptoms associated with dry eye disease.